Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924677 | 0.89 | ADRA1A (0.43) | ADRA1AMEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL4927947 | 0.89 | ADRA1A (0.43) | ADRA1AMEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL18747112 | 0.86 | ALOX5 (0.38) | ADRA1A | |
| SCHEMBL3702143 | 0.84 | ALDH1A1 (0.50) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL20707244 | 0.84 | DRD3 (0.36) | — | |
| SCHEMBL11087719 | 0.83 | ALDH1A1 (0.53) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL11086638 | 0.83 | ALDH1A1 (0.53) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL7978011 | 0.83 | GRM2 (0.44) | ADRA1ACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21518898 | 0.82 | ADRA1A (0.45) | ADRA1AMEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL21518900 | 0.82 | ADRA1A (0.45) | ADRA1AMEN1KMT2ACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336960-B2 | Lubricating compositions comprising thermoassociative and exchangeable copolymers | TOTAL MARKETING SERVICES (FR) | 2019-07-02 | — | — | US | disclosed |
| US-20170009176-A1 | LUBRICATING COMPOSITIONS COMPRISING THERMOASSOCIATIVE AND EXCHANGEABLE COPOLYMERS | TOTAL MARKETING SERVICES (FR) | 2017-01-12 | — | — | US | disclosed |
| US-20170009176-A1 | LUBRICATING COMPOSITIONS COMPRISING THERMOASSOCIATIVE AND EXCHANGEABLE COPOLYMERS | TOTAL MARKETING SERVICES (FR) | 2017-01-12 | — | — | US | disclosed |
| US-8465921-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2013-06-18 | — | — | US | disclosed |
| US-8465921-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2013-06-18 | — | — | US | disclosed |
| US-8465921-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2013-06-18 | — | — | US | disclosed |
| US-20110275070-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110275070-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110275070-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | disclosed |
| US-7794945-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | ELITECH HOLDING B.V. (NL) | 2010-09-14 | — | — | US | disclosed |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH BIOSCIENCES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-6884584-B2 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH BIOSCIENCES, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20050064463-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | DRUG ROYALTY LP1 (CA) | 2005-03-24 | — | — | US | disclosed |
| US-20040058322-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | US | disclosed |
| US-6492346-B1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | EPOCH PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1144429-A3 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | Epoch Pharmaceuticals, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6312894-B1 | HYBRIDIZATION OF OLIGONUCLEOTIDES AND MINOR GROOVE BINDER COMBINATION; WHERE THE MINOR GROOVE BINDER BINDS IN A NON-INTERCALATING MANNER WITH A HIGHER ASSOCIATION CONSTANT | EPOCH PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1144429-A2 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | Epoch Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-1999051621-A2 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | EPOCH PHARMACEUTICALS, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| US-5786512-A | Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1998-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050064463-A1 | Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders | DDB1, LIG3, MSH2 | ADRA1A 4291/4885MEN1 1857/4885KMT2A 3342/4885 |
| US-20090048427-A1 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS | DDB1, LIG3, MSH2 | ADRA1A 4291/4885MEN1 1857/4885KMT2A 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.